Therapeutic Antibody Market in China 2021
The therapeutic antibody market in China in terms of revenue is set to grow by US$ 41 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 30.4% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for therapeutic antibody. The China therapeutic antibody market is segmented on the basis of type. By type, it is categorized into antibody-drug conjugate (ADC), BsAb, monospecific Ab, and others.
The report has profiled some of the key players of the market such as 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Merck & Co., Novartis International AG, Roche Holding AG, Sinopharm Corporation Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the therapeutic antibody market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: antibody-drug conjugate (ADC), BsAb, monospecific Ab, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China therapeutic antibody market
Pinpoint growth sectors and trends for investment
Understand what the future of the therapeutic antibody market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for therapeutic antibody. The China therapeutic antibody market is segmented on the basis of type. By type, it is categorized into antibody-drug conjugate (ADC), BsAb, monospecific Ab, and others.
The report has profiled some of the key players of the market such as 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Merck & Co., Novartis International AG, Roche Holding AG, Sinopharm Corporation Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the therapeutic antibody market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: antibody-drug conjugate (ADC), BsAb, monospecific Ab, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China therapeutic antibody market
Pinpoint growth sectors and trends for investment
Understand what the future of the therapeutic antibody market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. THERAPEUTIC ANTIBODY MARKET BY TYPE
4.1 Antibody-Drug Conjugate (Adc)
4.2 Bsab
4.3 Monospecific Ab
4.4 Others
5. COMPANY PROFILES
5.1 3SBio Inc.
5.2 Bristol-Myers Squibb Company
5.3 Chengdu Kanghong Pharmaceutical Group Co., Ltd.
5.4 Jiangsu Hengrui Medicine Co., Ltd.
5.5 Merck & Co.
5.6 Novartis International AG
5.7 Roche Holding AG
5.8 Sinopharm Corporation Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. THERAPEUTIC ANTIBODY MARKET BY TYPE
4.1 Antibody-Drug Conjugate (Adc)
4.2 Bsab
4.3 Monospecific Ab
4.4 Others
5. COMPANY PROFILES
5.1 3SBio Inc.
5.2 Bristol-Myers Squibb Company
5.3 Chengdu Kanghong Pharmaceutical Group Co., Ltd.
5.4 Jiangsu Hengrui Medicine Co., Ltd.
5.5 Merck & Co.
5.6 Novartis International AG
5.7 Roche Holding AG
5.8 Sinopharm Corporation Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
